Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL334883 | 0.87 | MAPKAPK2 (0.47) | ALDH1A1ADRB3MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL10244514 | 0.81 | HTT (0.46) | PRMT6HTTHPGDALDH1A1ADRB3 | |
| SCHEMBL13181437 | 0.79 | HPGD (0.56) | HTTHPGDALDH1A1MEN1KMT2A | |
| SCHEMBL18575542 | 0.77 | CASR (0.48) | HTTALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL11508079 | 0.71 | HTT (0.51) | PRMT6HTTHPGDALDH1A1MEN1 | |
| SCHEMBL335330 | 0.70 | OPRK1 (0.50) | HTTALDH1A1ADRB3MEN1KMT2A | |
| SCHEMBL9004208 | 0.70 | CASR (0.42) | HTTALDH1A1ADRB3MEN1KMT2A | |
| SCHEMBL334407 | 0.70 | OPRK1 (0.50) | HTTALDH1A1ADRB3MEN1KMT2A | |
| SCHEMBL11023258 | 0.70 | HTT (0.59) | PRMT6HTTHPGDALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL11754584 | 0.69 | ADRB3 (0.64) | HTTADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1985620-A1 | 10a-AZALIDE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2008-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | PRMT6 1751/4885HTT 868/4885HPGD 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.